Curis slides as FDA retains partial hold on two portions of blood cancer study

Curis

30/08/2022 17:10

** Curis Inc's shares  CRIS.O  down 8.1% at $1
    ** U.S. FDA allows CRIS to resume patient enrollment in a
part of its early-to-mid stage study testing its experimental 
therapy emavusertib for blood cancer  urn:newsml:reuters.com:*:nPn5LRlfa
    ** However, the FDA said partial hold remains in place for
two other portions of the leukemia trial, CRIS says
    ** In April, FDA placed partial clinical hold on the study,
after the death of a patient
    ** The FDA in April had also placed a partial clinical hold
on a study of the drug to treat lymphoma; the hold on that trial
was lifted in August  urn:newsml:reuters.com:*:nL4N2ZU2HW
    ** Including session losses, stock down ~6% this year

 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))